MedPage Today May 20, 2024
— The agency pursued a handful of actions per year, allowed 61 of 62 mergers it challenged
The Federal Trade Commission (FTC) pursued about one merger action and three enforcement actions per year in the pharmaceutical industry over the last two decades, accounting for only a sliver of the alleged misconduct in the sector, a study of publicly available documents showed.
From 2000 to 2022, the FTC initiated or completed a total of 85 actions in the pharmaceutical sector, including 62 challenges of mergers, 22 enforcement actions against allegedly unlawful business practices, and one rule related to pharmaceuticals, reported Aaron Kesselheim, MD, JD, MPH, of Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues.
Of the 62...
Today's Sponsors
Today's Sponsor